Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Exercise to Improve Outcomes in Pancreatic Cancer (ExO-PanC)

13 juli 2026 bijgewerkt door: University of Surrey

Exercise-Based Pre-, Peri- and Post-Surgery Intervention to Improve Clinical and Translational Outcomes in Patients Undergoing Whipple's Procedure: A Feasibility Study.

Pancreatic cancer surgery (Whipple's procedure) is a major operation that can lead to reduced physical fitness, delayed recovery, and difficulty starting chemotherapy after surgery. Exercise before and after surgery may help improve recovery, but it is not known whether a personalised exercise programme delivered throughout the surgical pathway is practical or acceptable for patients.

The Exercise to Improve Outcomes in Pancreatic Cancer (ExO-PanC) study is a single-arm feasibility study that will recruit adults with suspected pancreatic ductal adenocarcinoma who are scheduled to undergo Whipple's procedure. Participants will receive an individualised exercise programme before surgery, during their hospital stay, and after discharge until the start of adjuvant chemotherapy. The programme will include aerobic exercise and resistance training prescribed according to each participant's fitness level.

The primary objective is to determine whether this exercise programme is feasible by assessing recruitment, participant adherence, compliance with the prescribed exercise programme, and retention. Secondary exploratory objectives include evaluating surgical complications, initiation of adjuvant chemotherapy, physical fitness, quality of life, nutritional status, and blood, stool, and tumour biomarkers associated with clinical outcomes. Findings from this feasibility study will inform the design of a future multicentre randomised controlled trial evaluating the effectiveness of the ExO-PanC programme.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Pancreatic ductal adenocarcinoma (PDAC) is associated with poor survival, reduced physical function, and a high burden of treatment-related morbidity. Patients undergoing pancreaticoduodenectomy (Whipple's procedure) often experience substantial declines in cardiorespiratory fitness and muscle function before and after surgery, which may contribute to postoperative complications, delayed recovery, and reduced likelihood of receiving adjuvant chemotherapy. While prehabilitation programmes are increasingly incorporated into routine care, current approaches are not typically individualised using objective measures of physical fitness and generally do not extend across the entire perioperative pathway.

The Exercise to Improve Outcomes in Pancreatic Cancer (ExO-PanC) study has been developed to evaluate the feasibility of a personalised exercise programme delivered before surgery, during hospital admission, and throughout postoperative recovery until the commencement of adjuvant chemotherapy. Exercise prescriptions will be individualised using cardiopulmonary exercise testing (CPET), muscle strength assessments, and functional performance measures, allowing exercise intensity and progression to be tailored to each participant's physiological capacity.

Participants will undergo repeated assessments of cardiorespiratory fitness, physical function, muscle strength, nutritional status, quality of life, and biological sampling throughout the study. Blood, stool, and surgically resected tumour tissue will be collected to explore biomarkers associated with clinical outcomes and responses to exercise.

The primary objective of this feasibility study is to determine whether the ExO-PanC intervention can be successfully delivered across the perioperative pathway by evaluating participant recruitment, adherence, compliance with prescribed exercise, and study retention. Exploratory analyses will investigate surgical complications, initiation of adjuvant chemotherapy, changes in physical fitness and quality of life, and relationships between biological markers and clinical outcomes.

Results from this study will establish the feasibility of implementing a personalised perioperative exercise programme for patients undergoing pancreatic cancer surgery and will provide essential data to inform the design of a future adequately powered multicentre randomised controlled trial evaluating the effectiveness of the ExO-PanC intervention.

Studietype

Ingrijpend

Inschrijving (Geschat)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Tarak AM Chouari, BSc (Hons) MBChB
  • Telefoonnummer: 01483688691
  • E-mail: t.chouari@nhs.net

Studie Locaties

  • Verenigd Koninkrijk
    • Surrey
      • Guildford, Surrey, Verenigd Koninkrijk, GU27XH
        • Werving
        • University of Surrey
        • Contact:
          • Tarak AM Chouari, BSc(Hons) MBChB
          • Telefoonnummer: 01483688691
          • E-mail: t.chouari@nhs.net
        • Onderonderzoeker:
          • Tarak AM Chouari, BSc(Hons) MBChB
        • Hoofdonderzoeker:
          • Adam E Frampton, PhD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Adults aged 18 years or older.
  • Planned to undergo upfront pancreatoduodenectomy (Whipple's procedure) for a suspected malignant periampullary mass.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • <18 years age
  • Cardiopulmonary exercise test (CPET) contraindications
  • Physical inability to perform CPET or undertake the program.
  • Lacking the capacity to consent
  • Unable to understand instructions in English
  • Not scheduled for surgery
  • A new diagnosis of Type 1 or Type 3c diabetes requiring management with insulin prescription will be excluded from the study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Intervention group
Participants will receive the ExO-PanC personalised exercise programme in addition to standard perioperative care. The intervention comprises four phases spanning the surgical pathway: prehabilitation before surgery, supervised inpatient exercise following surgery, structured home-based recovery after hospital discharge, and rehabilitation before commencement of adjuvant chemotherapy. Exercise is individually prescribed using cardiopulmonary exercise testing (CPET), muscle strength, and functional assessments, and includes aerobic and resistance with progression tailored to each participant's physical capacity. Participants also undergo repeated assessments of physical fitness, quality of life, nutritional status, and collection of blood, stool, and tumour tissue samples throughout the study.
Gedragsmatig: ExO-PanC Personalised Exercise Programme
Participants will receive the ExO-PanC personalised exercise programme alongside standard perioperative care. The intervention comprises four phases delivered across the surgical pathway: (1) prehabilitation before surgery, (2) supervised exercise during postoperative hospital admission, (3) structured home-based recovery following hospital discharge, and (4) rehabilitation before the commencement of adjuvant chemotherapy. Exercise prescriptions are individualised using cardiopulmonary exercise testing (CPET), muscle strength, and functional assessments. The programme includes aerobic, resistance, flexibility, and home-based exercise, with intensity and progression tailored to each participant's fitness level. Exercise may be delivered in supervised or semi-supervised formats, with heart rate monitoring used to support exercise prescription and progression. Participants continue to receive all standard NHS perioperative care throughout the study.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Feasibility of the ExO-PanC exercise programme
Tijdsspanne: From enrolment until completion of the intervention (approximately 16-24 weeks)
Feasibility will be assessed using participant recruitment, adherence to the prescribed exercise programme (target >85% of prescribed sessions completed), compliance with prescribed exercise intensity, duration and type (target >80%), and participant retention (target <20% withdrawal for non-clinical reasons). Feasibility will be evaluated separately across the preoperative, perioperative and postoperative phases of the intervention.
From enrolment until completion of the intervention (approximately 16-24 weeks)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Postoperative surgical complications
Tijdsspanne: Up to approximately 6 weeks following surgery.
Occurrence and severity of postoperative complications, including pancreatic fistula and other clinically relevant surgical complications
Up to approximately 6 weeks following surgery.
Commencement and completion of adjuvant chemotherapy
Tijdsspanne: From surgery until planned commencement and completion of adjuvant chemotherapy.
Proportion of participants who commence planned adjuvant chemotherapy following pancreaticoduodenectomy and proportion who complete it
From surgery until planned commencement and completion of adjuvant chemotherapy.
Cardiorespiratory fitness (CRF) measured by cardiopulmonary excercise testing (CPET)
Tijdsspanne: Baseline through completion of the intervention (approximately 16-24 weeks)
Difference in anaerobic threshold (mL/kg/min) and peak oxygen uptake (VO₂peak, mL/kg/min) measured during CPET.
Baseline through completion of the intervention (approximately 16-24 weeks)
Muscle strength
Tijdsspanne: Baseline through completion of the intervention (approximately 16-24 weeks).
Changes in upper and lower body muscle strength measured using standardised strength assessments.
Baseline through completion of the intervention (approximately 16-24 weeks).
Change in health-related quality of life measured using the EORTC QLQ-C30
Tijdsspanne: Serial measurements from baseline through completion of the intervention (approximately 16-24 weeks).
Health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Change in EORTC QLQ-C30 global health status, functional scales and symptom scales. Scores range from 0-100.
Serial measurements from baseline through completion of the intervention (approximately 16-24 weeks).
Nutritional status
Tijdsspanne: Baseline through completion of the intervention (approximately 16-24 weeks).
Nutritional status assessed using the Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF).
Baseline through completion of the intervention (approximately 16-24 weeks).
Change in pancreatic cancer-specific quality of life measured using the EORTC QLQ-PAN26
Tijdsspanne: This will be measured at five timepoints from recruitment through to commencement of adjuvant chemotherapy
Serial changes in EORTC QLQ-PAN26 symptom scores. Scores range from 0-100.
This will be measured at five timepoints from recruitment through to commencement of adjuvant chemotherapy

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

University of Surrey

Medewerkers

Royal Surrey County Hospital NHS Foundation Trust

Onderzoekers

  • Hoofdonderzoeker: Adam E Frampton, PhD, University of Surrey

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

6 juli 2026

Primaire voltooiing (Geschat)

1 juni 2029

Studie voltooiing (Geschat)

1 juni 2030

Studieregistratiedata

Eerst ingediend

6 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

13 juli 2026

Eerst geplaatst (Werkelijk)

17 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

13 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 350182

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren